drugset
drugset / Trial / NCT01905228

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

NCT01905228 ↗

Phase 1 Completed 83 enrolled Incuron
NaSequentialOpen-labelTreatment

Summary

This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.

Timeline

Start
2013-07
Primary completion
2019-05
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CBL0137 Other / unclassified 150 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 180 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 240 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 320 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 400 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 540 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 700 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 920 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 1200 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 1600 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 2100 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 2700 mg/m2 Intravenous

Indications

glioblastoma